Naltrexone in Two Models of Psychosocial Treatments for Cocaine and Alcohol Dependence
| Status: | Completed |
|---|---|
| Conditions: | Psychiatric, Pulmonary |
| Therapuetic Areas: | Psychiatry / Psychology, Pulmonary / Respiratory Diseases |
| Healthy: | No |
| Age Range: | 18 - 65 |
| Updated: | 4/21/2016 |
| Start Date: | January 1998 |
| End Date: | July 2003 |
Naltrexone and Psychosocial Treatments for the Treatment of Cocaine Dependence Complicated by Alcohol Dependence
The purpose of this study is to see whether naltrexone is safe and useful in preventing
alcohol relapse, as well as in decreasing craving for alcohol in people with a diagnosis of
alcohol and cocaine dependence. Naltrexone is approved by the Food and Drug Administration
(FDA) for the treatment of alcohol dependence. However, the medication was not approved as
yet at the dosage we will use in this study. The dosage we will use for the study (150 mg),
is greater than the recommended dosage from the Physician's Desk Reference (50mg). Unlike
other medicines (like Antabuse) useful in the treatment of alcohol dependence, naltrexone
will not make you sick if you drink alcohol. Rather, people who are taking this medication
have reported that it helps decrease the pleasure associated with drinking for them. This
study is being conducted because the medication (Naltrexone) has not been well studied in
people with both alcohol and cocaine dependence, so it is still investigational.
We believe that if we can reduce alcohol consumption through naltrexone and psychotherapy,
this may lead to reduced cocaine use. We are also conducting this study to test two
different types of psychotherapy as a method for reducing cocaine and alcohol use. One type
of psychotherapy is designed to help people learn to cope with situations that put them at
high risk for relapse to cocaine and/or alcohol use. The other type of psychotherapy we will
use focuses on strengthening motivation to recover from cocaine and/or alcohol use, and on
developing techniques to handle possible barriers to recovery. We seek to enroll 300
patients in the study.
alcohol relapse, as well as in decreasing craving for alcohol in people with a diagnosis of
alcohol and cocaine dependence. Naltrexone is approved by the Food and Drug Administration
(FDA) for the treatment of alcohol dependence. However, the medication was not approved as
yet at the dosage we will use in this study. The dosage we will use for the study (150 mg),
is greater than the recommended dosage from the Physician's Desk Reference (50mg). Unlike
other medicines (like Antabuse) useful in the treatment of alcohol dependence, naltrexone
will not make you sick if you drink alcohol. Rather, people who are taking this medication
have reported that it helps decrease the pleasure associated with drinking for them. This
study is being conducted because the medication (Naltrexone) has not been well studied in
people with both alcohol and cocaine dependence, so it is still investigational.
We believe that if we can reduce alcohol consumption through naltrexone and psychotherapy,
this may lead to reduced cocaine use. We are also conducting this study to test two
different types of psychotherapy as a method for reducing cocaine and alcohol use. One type
of psychotherapy is designed to help people learn to cope with situations that put them at
high risk for relapse to cocaine and/or alcohol use. The other type of psychotherapy we will
use focuses on strengthening motivation to recover from cocaine and/or alcohol use, and on
developing techniques to handle possible barriers to recovery. We seek to enroll 300
patients in the study.
Inclusion Criteria::
- Male and females, 18-65 years old.
- Meets DSM-IV criteria for current diagnoses of cocaine and alcohol dependence,
determined by the SCID.
- In the past 30 days, S used no less than $200-worth of cocaine and >15 standard
alcohol drinks (avg)/week with at least 1 day of 4 or more drinks, determined by the
TLFB--adapted to collect daily cocaine use.
- Successful completion of medical detoxification, i.e., 5 consecutive days of
abstinence from cocaine and alcohol, via self-reports and negative urine toxicology
screens.
- Lives a commutable distance to the TRC and agrees to follow-up visits.
- Understands and signs the consent.
Exclusion Criteria::
- Abstinent from cocaine or alcohol for 30 days prior to signing consent form. (S may
have been institutionalized in the prior month and still be eligible if his/her
cocaine and alcohol use that month met inclusion criteria.)
- Current DSM-IV diagnosis of any substance dependence other than cocaine, alcohol,
nicotine, or cannabis determined by the SCID.
- Evidence of opiate use in the past 30 days, determined by self-report on the SCID or
ASI, and/or by a urine drug screen that is positive for opiates at treatment entry.
- Current treatment with psychotropic medications (excluding short-term use of
benzodiazepines for detoxification), including disulfiram.
- History of unstable or serious medical illness, including need for opioid analgesics.
- History of epilepsy or seizure disorder.
- Severe physical or medical illnesses such as AIDS, active hepatitis, significant
hepatocellular injury as evidenced by elevated bilirubin levels, or elevated levels
over 3.5x normal of aspartate aminotransferase (AST), and serum glutamic-pyruvic
transaminase (SGPT).
- Current severe psychiatric symptoms, e.g., psychosis, suicidal or homicidal ideation
or mania.
- Use of an investigational medication in the past 30 days.
- Female Ss who are pregnant, nursing, or not using a reliable method of contraception.
[Note: Criteria 4-10 will be assessed via the medical exam plus results from lab
tests.]
We found this trial at
1
site
Click here to add this to my saved trials
